Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Inflammatory Bowel Disease Treatment Market

Inflammatory Bowel Disease Treatment Market Size

  • Report ID: GMI10194
  • Published Date: Jul 2024
  • Report Format: PDF

Inflammatory Bowel Disease Treatment Market Size

Inflammatory Bowel Disease Treatment Market size was valued at USD 22.6 billion in 2023 and is anticipated to witness growth at a CAGR of 6.1% between 2024 and 2032. The inflammatory bowel disease (IBD) treatment market is experiencing growth driven by the increasing prevalence of IBD, favorable reimbursement policies, and growing awareness and early diagnosis of IBD symptoms.

 

IBD, which includes conditions such as Crohn's disease and ulcerative colitis, is becoming more common worldwide, impacting millions of individuals and placing a substantial burden on healthcare systems. For instance, according to the Centers for Disease Control and Prevention, in 2024, an estimated 7 million people worldwide have IBD. Several factors contribute to the rising prevalence of IBD, including genetic predisposition, environmental influences, and lifestyle changes. Urbanization and poor diets, characterized by high fat and low fibre, are associated with higher IBD incidence rates. Additionally, improved diagnostic techniques and greater awareness among healthcare providers have led to higher detection rates, contributing to the perceived increase in prevalence.
 

Inflammatory bowel disease treatment refers to the medical management and therapeutic interventions aimed at controlling and alleviating the symptoms of chronic inflammatory conditions of the gastrointestinal tract, primarily Crohn's disease and ulcerative colitis. The primary goals of IBD treatment are to induce and maintain remission, reduce inflammation, prevent complications, and improve the overall quality of life for patients.
 

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Inflammatory bowel disease treatment industry size was USD 22.6 billion in 2023 and is projected to expand at 6.1% CAGR from 2024 to 2032, on account of the increasing prevalence of IBD, and growing awareness and early diagnosis of IBD symptoms.

The TNF inhibitors drug class segment in the inflammatory bowel disease treatment industry is projected to account for USD 11.1 billion by 2032, owing to their high efficacy in reducing inflammation and inducing and maintaining remission.

The injectable route of administration segment in the inflammatory bowel disease treatment industry accounted for USD 17.3 billion in 2023 and is projected to grow at notable rate between 2024 and 2032, as they are known for their high efficacy and rapid onset of action.

North America inflammatory bowel disease treatment industry recorded USD 9 billion in revenue in 2023 and is projected to grow at 5.5% CAGR from 2024 to 2032, due to its advanced healthcare infrastructure and high adoption rate of innovative inflammatory bowel disease treatment technologies.

Inflammatory Bowel Disease Treatment Market Scope

Buy Now


Premium Report Details

  • Base Year: 2023
  • Companies covered: 14
  • Tables & Figures: 151
  • Countries covered: 23
  • Pages: 100
 Download Free Sample